Global AI in Pharmacovigilance Market Size & Trends Report Segmented by Component (Software, Services), Deployment (On-premises, Cloud-based), End-user (Pharmaceutical & Biotech Companies, CROs) & Regional Forecasts to 2030

The AI in pharmacovigilance market is expected to grow at a CAGR of 12 -15% from 2023 to 2030, driven by the need to automate adverse event data processing, stringent regulatory requirements, advancements in AI analytics, cost reduction benefits, and the increasing use of real-world evidence. These factors reshape pharmacovigilance processes, ensuring faster and more accurate safety assessments. However, high implementation costs and data privacy concerns pose challenges to the market growth

Report Overview

Artificial intelligence (AI) in pharmacovigilance refers to applying machine learning, natural language processing, and other AI technologies to enhance the monitoring, detection, assessment, and prevention of adverse drug reactions and related issues. It helps streamline the traditionally manual processes involved in pharmacovigilance by automating data extraction, signal detection, and case processing. AI facilitates faster and more accurate analysis of large datasets, ensuring regulatory compliance and improving drug safety. The technology is particularly valuable in managing the complexities of real-world data, including unstructured information from medical records, social media, and adverse event reports.

To learn more about this report, download the PDF brochure

Growing Volume of Adverse Event Data

The increasing volume and complexity of adverse drug reaction (ADR) data are major factors driving the adoption of AI in pharmacovigilance. With the rise of global drug usage and access to various reporting channels, pharmacovigilance teams are overwhelmed by the sheer amount of structured and unstructured data generated daily. AI technologies, such as machine learning and natural language processing, enable efficient data extraction, deduplication, and classification from disparate sources, such as electronic health records, social media, and clinical trial databases. Automating these processes reduces human errors and ensures faster identification of potential safety signals, allowing quicker interventions. This capability is especially crucial as pharmaceutical companies face stringent timelines to comply with regulatory requirements and ensure public safety. By leveraging AI, the industry can handle data growth while maintaining cost efficiency and precision.

Integration of AI with Real-World Data Analytics

One significant advancement boosting the market is the integration of AI with real-world data (RWD) analytics in pharmacovigilance. RWD, sourced from electronic medical records, wearable devices, and patient registries, offers valuable insights into drug safety and efficacy in real-life settings. AI-powered algorithms can process and analyze these vast datasets to detect adverse drug reactions and patterns that might go unnoticed in clinical trials. Additionally, AI enables the identification of rare or long-term side effects through predictive modeling and signal detection. This integration enhances proactive safety monitoring, improves decision-making, and aids in personalized medicine approaches. As regulators increasingly recognize the importance of RWD in drug safety evaluations, the use of AI-driven RWD analytics has become a transformative force in the pharmacovigilance landscape, offering faster and more accurate results to safeguard patient health.

To learn more about this report, download the PDF brochure

Competitive Landscape Analysis

The global AI in pharmacovigilance market is marked by the presence of established and emerging market players such as WNS, Accenture Plc, IQVIA Inc, Oracle, PAREXEL International Corporation, Cognizant and Aris Global among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

Report Scope

Report Metric	Details
Base Year Considered	2024
Historical Data	2023 - 2024
Forecast Period	2025 - 2030
Growth	12-15%
Market Drivers	Rising volume of adverse event data requiring automation Growing regulatory emphasis on drug safety and compliance Advancements in AI-powered predictive analytics Increasing use of real-world evidence for safety monitoring Expanding global drug development and post-market surveillance
Attractive Opportunities	Use of AI in signal detection and adverse event prediction Increasing adoption of cloud-based pharmacovigilance solutions Adoption of AI to reduce operational costs and improve accuracy Growing collaborations between AI companies and pharmaceutical firms
Segment Scope	Component, Deployment and End-user
Regional Scope	North America (US & Canada) Europe (UK, Germany, France, Italy, Spain, Rest of Europe) Asia Pacific (China, India, Japan, Rest of Asia Pacific) Latin America Middle East & Africa
Key Companies Mapped	WNS, Accenture Plc, IQVIA Inc, Oracle, PAREXEL International Corporation, Cognizant and Aris Global among others
Report Highlights	Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis

Global AI in Pharmacovigilance Market Segmentation

This report by Medi-Tech Insights provides thesize of the global AI in pharmacovigilance market at theregional- and country-level from 2023 to 2030. The report further segments the market based on component, deployment and end-user.

• Market Size & Forecast (2023-2030), By Component, USD Million

  • Software
  • Services

• Market Size & Forecast (2023-2030), By Deployment, USD Million

  • On-premises
  • Cloud-based

• Market Size & Forecast (2023-2030), By End-user, USD Million

  • Pharmaceutical and Biotech Companies
  • Contract Research Organizations (CROs)
  • Others

• Market Size (2023-2030), By Region, USD Million

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa